The outcome of patients with follicular lymphoma in the rituximab era treated with autologous stem cell transplant according to the high-dose regimen received. A retrospective study of the EBMT Lymphoma Working Party.
Abstract
The aim of this study was to investigate the outcome of patients with FL having ASCT according to the high-dose regimen (TBI vs. BEAM) and previous treatment with rituximab.
The use of rituximab prior to ASCT had no detrimental impact on outcome and in fact was associated with significantly better overall survival and event free survival.